“Historic moment:” Today, the FDA gave Biogen’s investigational Alzheimer’s drug aducanumab its approval, with the requirement that they conduct a post-approval trial. In a…
We talked with Banner Alzheimer’s Institute Director Pierre Tariot about the most recent results from Eli Lilly’s Alzheimer’s trial for donanemab — what he…
If aducanumab — an experimental treatment that may slow the progression of Alzheimer’s — gets FDA approval, how will the healthcare system meet the anticipated…
“Can I look into your future and can I accurately estimate how much beta-amyloid you’re going to accumulate over the next two years, the…
While some scientists are focused on targeting beta-amyloid plaques to treat Alzheimer’s, others are honing in on another hallmark of the disease — pathological…
In a new field of research, scientists are studying whether microorganisms in the gut may influence brain health and Alzheimer’s. Researchers have found that…
People with Down syndrome are more likely to develop Alzheimer’s disease than the general population. Scientists believe that studying Down syndrome may offer vital…